EUVIMEDEUVIMED entdecken
Crossref

Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia

Agostino Cianciulli, Andrea Bernardelli, Stefania Faedo, Elisabeth Le, Carmen Methner, Annalisa Pellacani, Teresa Semeraro, Iuni M L Trist, Sanjiv Kaul iD, Fabrizio Micheli iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202500662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Agostino Cianciulli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aptuit, an Evotec Company, Campus Levi-Montalcini, Via Alessandro Fleming 4, 37135, Verona, Italy. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Myocardial Ischemia, Vasodilator Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Aptuit an Evotec Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following up on the discovery of multiple series of GPR39 antagonists via high‐throughput screening (HTS), appropriate hit expansion and medicinal chemistry efforts lead to the identification of potent and selective GPR39 antagonists. Among these, compound 61 emerges as the front runner of this series, demonstrating high potency, appropriate physicochemical properties governing systemic exposure, in both rat and dog, and the absence of undesired off‐target pharmacology such as cardiac ion channels (i.e., hERG, hNav1.5, and Cav1.2). In vivo evaluations show compound 61 to be a selective coronary vasodilator that reduced no‐reflow and infarct size in a rodent model of ischemia‐reperfusion. This first‐in‐class drug demonstrates the benefit of GPR39 inhibition in myocardial ischemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledMyocardial IschemiaVasodilator AgentsAnimalsDogsRatsStructure-Activity RelationshipHumansMolecular StructureDose-Response Relationship, DrugRats, Sprague-DawleyMale

Stichwörter der Autor:innen

7TMGPR39acute myocardial infarctionischemiapericytes

Substanzen

Receptors, G-Protein-CoupledVasodilator Agents

Autor:innen und Institutionen

  • Aptuit, an Evotec Company, Campus Levi-Montalcini, Via Alessandro Fleming 4, 37135, Verona, Italy.
  • Knight Cardiovascular Institute, Oregon Health and Science University, UHN 62, Portland, OR, 97239, USA.
  • Vasocardea Inc., 2010 SW Carter Lane, Portland, OR, 97239, USA.

ORCID-Profile: Sanjiv Kaul, Fabrizio Micheli

Förderung

  • Aptuit an Evotec Company

Zitieren

APA

Cianciulli, A., Bernardelli, A., Faedo, S., Le, E., Methner, C., Pellacani, A., Semeraro, T., Trist, I. M. L., Kaul, S., & Micheli, F. (2026). Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia. ChemMedChem. https://doi.org/10.1002/cmdc.202500662

Vancouver

Cianciulli A, Bernardelli A, Faedo S, Le E, Methner C, Pellacani A, et al. Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia. ChemMedChem. 2026. doi:10.1002/cmdc.202500662

BibTeX
@article{Cianciulli2026,
  author = {Cianciulli, Agostino and Bernardelli, Andrea and Faedo, Stefania and Le, Elisabeth and Methner, Carmen and Pellacani, Annalisa and Semeraro, Teresa and Trist, Iuni M L and Kaul, Sanjiv and Micheli, Fabrizio},
  title = {Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202500662}
}
Kostenlos starten →